Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PLEC | Q15149 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6248837 | 0.98 | TTR (0.40) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL31668182 | 0.97 | TTR (0.41) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL9319210 | 0.97 | TTR (0.41) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL20659945 | 0.94 | TTR (0.41) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL6053862 | 0.93 | CYP3A4 (0.43) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL27515109 | 0.93 | TTR (0.40) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL29586703 | 0.88 | TTR (0.43) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL7750809 | 0.80 | TTR (0.39) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL87887 | 0.79 | HCAR2 (0.43) | TTRCYP3A4TSHRTDP1AKR1C4 | |
| SCHEMBL1122760 | 0.79 | HCAR2 (0.43) | TTRCYP3A4TSHRTDP1AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582703-B2 | Blood substitutes comprising hemoglobin and methods of making | VirTech Bio, Inc. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20230090172-A1 | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHOGS OF MAKING | VirTech Bio, Inc. | 2023-03-23 | — | — | US | disclosed |
| US-11504417-B2 | Blood substitutes comprising hemoglobin and methods of making | VirTech Bio, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220296685-A1 | Uricase Derivative Co-conjugated With Fatty acid-linked PEG and optionally, Alkoxy PEG | BONE SOLUTIONS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20200222510-A1 | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING | VirTech Bio, Inc. | 2020-07-16 | — | — | US | disclosed |
| EP-3655019-A1 | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING | Virtech Bio, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019018403-A1 | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING | VIRTECH BIO, LLC (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-0361719-B1 | Haemoglobin based blood substitute and method for the preparation thereof | TECHNION RES & DEV FOUNDATION (IL) | 1994-01-12 | — | — | EP | disclosed |
| EP-0361719-A1 | Haemoglobin based blood substitute and method for the preparation thereof | Technion Research & Development Foundation Ltd. (IL) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222510-A1 | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHODS OF MAKING | HBG1, HBG2, HBB | TTR 18/4885CYP3A4 1571/4885TSHR 3305/4885 |
| US-11504417-B2 | Blood substitutes comprising hemoglobin and methods of making | HBG1, HBG2, HBB | TTR 18/4885CYP3A4 1571/4885TSHR 3305/4885 |
| US-20230090172-A1 | BLOOD SUBSTITUTES COMPRISING HEMOGLOBIN AND METHOGS OF MAKING | HBG1, HBG2, HBB | TTR 16/4885CYP3A4 1617/4885TSHR 2845/4885 |
| US-20220296685-A1 | Uricase Derivative Co-conjugated With Fatty acid-linked PEG and optionally, Alkoxy PEG | ELOVL3, LIPC, ELOVL6 | TTR 1180/4885CYP3A4 1326/4885TSHR 3018/4885 |
| US-12582703-B2 | Blood substitutes comprising hemoglobin and methods of making | HBB, HBG2, HBG1 | TTR 61/4885CYP3A4 969/4885TSHR 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.